The developers are exploring clinical applications with a view to making a platform available in a few years for testing at the point of care and in remote settings.
In a newly published study, an algorithm developed at NIH shows promise for improving early detection of cervical cancer in low-resource areas, where 80 percent of cases occur.
New drugs, tests, and policies suggest steady and continued future growth in the space, though public awareness of personalized medicine continues to lag.
Excluding IPOs, the funding environment for private venture-backed financing Dx deals in the US and Europe was remarkably similar in 2018 to 2017, according to Silicon Valley Bank.
During the year, the growing threat of antimicrobial resistance drove development and adoption of advanced diagnostic tests, including molecular testing.
The company will use its NeoType Discovery Panel for the trial. The panel assesses 320 cancer-related genes in solid tumors, hematologic malignancies, and advanced sarcomas.
